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The casein kinase 2 (CK2) protein kinase is a pro-survival kinase and therapeutic target
in treatment of various human cancers. CK2 overexpression has been demonstrated
in hematological malignancies, including chronic lymphocytic leukemia, chronic myeloid
leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma.
CX-4945, also known as Silmitasertib, is an orally administered, highly specific, ATP-
competitive inhibitor of CK2. CX-4945 induces cytotoxicity and apoptosis and is currently
being evaluated in clinical trials for treatment of many cancer types. In the past 2 years,
the focus on the therapeutic potential of CX-4945 has shifted from solid tumors to
hematological malignancies. CX-4945 exerts anti-proliferative effects in hematological
tumors by downregulating CK2 expression and suppressing activation of CK2-mediated
PI3K/Akt/mTOR signaling pathways. Furthermore, combination of CX-4945 with other
inhibitors yielded synergistic effects in cell death induction. These new findings demon-
strate that CK2 overexpression contributes to blood cancer cell survival and resistance
to chemotherapy. Combinatorial use of CX-4945 is a promising therapeutic tool for
treatment of hematological malignancies.
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Introduction
Among the diverse types of human cancers, hematologic or lymphoid malignancies present
major therapeutic challenges due to their low survival rates and poor prognosis. New immuno-
chemotherapeutic approaches have improved the survival rates overall; however, many patients
with hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and chronic myeloid
leukemia (CML), still have poor outcomes due to resistance to chemotherapy, personal therapeutic
limits, frequent metastasis, and relapse (Faderl et al., 2009; Gribben and O’Brien, 2011). Thus,
there is a need for new and more sophisticated therapeutic strategies for treatment of hematologic
malignancies.
The serine/threonine protein kinase, CK2 (casein kinase 2), modulates multiple signaling path-
ways involved in hematopoietic cell survival and function, and is therefore a promising drug target
(Dominguez et al., 2009; Trembley et al., 2009; Piazza et al., 2012). CK2 is constitutively expressed in
many cell types. In human cells it typically exists as a tetrameric complex comprising two catalytic
alpha subunits (a and a0) and two regulatory (b) subunits (Litchfield, 2003). CK2 plays an important
role in the regulation and phosphorylation of a broad range of cellular targets (Pinna, 1990; Litchfield
and Lüscher, 1993; Allende and Allende, 1995; Pinna and Meggio, 1997; Guerra and Issinger, 1999;
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Faust and Montenarh, 2000). In mice, knockout of the CK2a0
subunit induces developmental defects and knockdown of the
CK2a and b subunits results in embryonic lethality (Lou et al.,
2008; Seldin et al., 2008). CK2 regulates hematopoiesis-associated
signaling cascades as well as multiple biochemical processes
involving tumor growth, proliferation, and resistance to cytotoxic
agents (Piazza et al., 2012). In normal cells, CK2 shows ubiquitous
localization throughout the nuclear and cytoplasmic compart-
ments, whereas, in cancer cells, CK2 shows greater abundance
in the nuclear compartment (Faust et al., 1999; Laramas et al.,
2007). This difference in CK2 distributionmay be significant with
regard to its biochemical function in cancer. CK2 overexpression
has been observed in many hematologic cancers, including CLL
(Martins et al., 2010), multiplemyeloma (MM; Piazza et al., 2006),
T-cell acute lymphocytic leukemia (T-ALL; Silva et al., 2008), and
acute myeloid leukemia (AML; Kim et al., 2007; Quotti Tubi et al.,
2013). These studies found that CK2a/b mRNA or protein level
was increased in cells from several AML patients (approximately
2- to 14-fold more, compared to controls; Quotti Tubi et al., 2013)
or from CLL patients (approximately twofold more, compared
controls; Martins et al., 2010), as well as plasma cells from MM
patients (CK2a, 88% and CK2b, 64% of MM patients analyzed;
Manni et al., 2013). Moreover, CK2 upregulation was correlated
with poor prognosis (Trembley et al., 2009). These studies identify
CK2 as a promising therapeutic target for the development of
anti-cancer agents for treatment of many hematological cancers.
Downregulation of CK2 and Cancer Cell
Survival
Overexpression of CK2 has been observed in many cancers,
including hematologic cancers such as AML, CLL, T-ALL, and
MM (Piazza et al., 2006; Kim et al., 2007; Silva et al., 2008;Martins
et al., 2010). Downregulation of CK2, either by transfection of
specific siRNA or plasmid-based expression of kinase-inactive
CK2, resulted in reduction of cancer cell viability and induc-
tion of apoptosis (Faust et al., 2000; Wang et al., 2001; Slaton
et al., 2004). Similar to studies addressing non-hematological
cancers, RNA interference that targets CK2 was found to induce
apoptosis in MM, AML, CLL, and CML (Borgo et al., 2013;
Manni et al., 2013; Quotti Tubi et al., 2013; Martins et al.,
2014). These reports suggest that downregulation of CK2 by
RNA interference or CX-4945 treatment enhances cytotoxicity of
hematological cancer cells. Consistent with the overexpression-
related observations, these downregulation experiments indicate
that CK2 may be a valid druggable anti-cancer target for use in
treatment of hematological malignancies, not only human solid
tumors (Sarno et al., 2002; Martins et al., 2010; Kim and Kim,
2012).
CX-4945
CX-4945 (Silmitasertib) is an orally administered, ATP-
competitive inhibitor of both CK2a and CK2a0 catalytic subunits
that was first developed byCylene Pharmaceuticals Inc. (Siddiqui-
Jain et al., 2010; Pierre et al., 2011b). CX-4945 has been
investigated in human cancer studies worldwide and is currently
in Phase I and II clinical trials (ClinicalTrials.gov Identifier:
NCT02128282). The Phase I trial addresses the safety and
tolerability of increasing doses of CX-4945 in combination with
gemcitabine plus cisplatin, to determine the maximum tolerated
dose (MTD). The subsequent Phase II trial is a randomized
study of antitumor activity in cholangiocarcinoma patients,
comparing the standard-of-care protocol of gemcitabine plus
cisplatin against treatment with CX-4945 in combination with
gemcitabine plus cisplatin at the combination MTD determined
in the preceding trial.
Mechanism of CX-4945 Inhibition of CK2
In the molecular model of inhibition, hydrophobic residues in the
small and flat ATP binding site of the CK2a subunit can bind ATP
or CK2 inhibitors (Sarno et al., 2005). Downregulation of CK2
kinase activity is expected to be due to the ability of inhibitors
to establish polar interactions with the active conformation of
CK2a. CX-4945 showed a strong interactionwith theATPbinding
pocket of CK2, with a K i = 0.38 [0.02 nM with the recombinant
human holoenzyme (aabb; Ferguson et al., 2011)]. This strong
binding interaction between CX-4945 and the ATP binding site
of CK2 reduces the enzymatic activity and attenuates the down-
stream, CK2-regulated PI3K/Akt signaling pathway (Pierre et al.,
2011a). The mechanistic relationship between CK2 inhibition by
CX-4945, the downstream signaling pathways, and cancer cell
survival remains to be fully elucidated.
The Effect of CX-4945 in Human
Lymphocytic/Lymphoblastic Malignancies
The efficacy of CX-4945 has been evaluated with a broad range
of human hematologic tumors, including CLL, ALL, AML, and
lymphomas (Prins et al., 2013). These studies demonstrated that
CX-4945 exerts strong anti-proliferative activity in CLL biopsy
samples. As well as decreasing CLL cell viability (IC50 < 1 mM)
when used alone, CX-4945 exerted synergistic effects in combi-
nation with several other inhibitors, including GS-1101, ibrutinib,
and fludarabine, which regulate B-cell receptor (BCR)-mediated
signaling cascades or downstream mediators. CK2 inhibition
downregulates signaling mediators that act downstream of BCR,
including PI3K and Akt (Martins et al., 2010, 2011; Ruzzene and
Pinna, 2010; Piazza et al., 2012).
In primary CLL cells and in the stable CLL cell line MO1043,
CX-4945 treatment led to decreased phosphorylation of Akt and
PKC, which are downstream targets of PTEN and PI3K (Martins
et al., 2014). Consistent with the in vitro effects observed in
CLL cells, CX-4945 also showed anti-tumor activity in a mouse
xenograft model. CX-4945 treatment caused delayed tumor
growth, and treatment with CX-4945 plus fludarabine showed
synergistic effects. This pre-clinical evidence suggests that CX-
4945 is likely to show therapeutic activity, and that it represents
a good candidate for CLL treatment in combination with other
anti-tumor agents.
CK2 overexpression is a hallmark of ALL, and two recent
studies investigated the relationship between increased CK2
expression and the cytotoxic activity of CX-4945 in T-cell ALL and
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FIGURE 1 | Schematic of CK2-mediated signaling pathways inhibited by CX-4945.
TABLE 1 | Anti-cancer drugs for potential combination therapy with CX-4945 in treatment of human hematological cancers.
Disease Target CK2 subunits Combined inhibitors Target IC50 or Ki Reference
CLL a, a0 Ibrutinib BTK (Bruton’s tyrosine kinase) 0.5 nM (Ki) Honigberg et al. (2010)
ALL a, a0 Temsirolimus mTOR 1.76 mM Shor et al. (2008)
CML a, b Imatinib Bcr-Abl 0.6 mM Buchdunger et al. (1995)
AML a, b Daunorubicin DNA or RNA synthesis 0.02 mM Gewirtz (1999)
MM a, b Bortezomib 20S proteasome 0.6 nM (Ki) Adams et al. (1999)
B-cell ALL (Buontempo et al., 2014; Gomes et al., 2014). CK2 was
found to induce phosphorylation of the PTEN tumor suppressor
and thereby to activate PI3K/Akt/mTOR, which is a signaling
axis that is important for cell survival in ALL (Torres and Pulido,
2001; Vázquez-Franco et al., 2012; Huang et al., 2013; Carnero and
Paramio, 2014). CX-4945 treatment resulted in apoptosis of T-cell
ALL and B-cell ALL cells (Buontempo et al., 2014; Gomes et al.,
2014).
The Effect of CX-4945 in Human Myeloid
Cancers
The therapeutic activity of CX-4945 was also evaluated in CML
and AML, respectively. CML is characterized by a transloca-
tion known as the “Philadelphia chromosome,” which results
in the fusion protein Bcr-Abl, a protein tyrosine kinase that
plays a crucial role in cell proliferation and in maintenance of
the CML phenotype (Goldman and Melo, 2003). A relationship
between Bcr-Abl andCK2 has been previously suggested (Hériché
and Chambaz, 1998; Mishra et al., 2003, 2007). Borgo et al.
(2013) demonstrated that CX-4945 showed anti-tumor activity in
imatinib-resistantCML cells. Downregulation ofCK2byCX-4945
or siRNA contributed to the induction of apoptotic cell death.
Furthermore, CK2 inhibition affected the sensitivity of AML cells
to chemotherapy. Downregulation of CK2 by CX-4945, K27, or
siRNA showed synergistic effects on cytotoxicity and apoptosis
in acute, primary blasts as well as in AML cell lines (Quotti Tubi
et al., 2013). Moreover, CX-4945 increased the chemotherapeutic
activity of daunorubicin in AML.
Perspective on Combination Therapy
with the CK2 Inhibitor, CX-4945,
in Hematological Cancers
Inhibition of CK2 expression could also be useful in combination
therapies for treatment of MM andmantle cell lymphoma (MCL).
A recent report demonstrated CK2 overexpression in MM and
MCL cells and that downregulation of CK2 with CK2 inhibitors,
such as CX-4945 and K27, induced apoptosis (Manni et al., 2013).
Bortezomib, a proteasome inhibitor, exerted anti-tumor activity
in MM and MCL cells by stabilization of IkBa in the NF-kB
signaling pathway; however, bortezomib alone proved to be insuf-
ficient for effective treatment. When used in conjunction with
bortezomib, CX-4945 inhibition of CK2 enhanced the cytotoxic
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activity andmitochondrial-dependent cell death inMMandMCL
cells (Manni et al., 2013).
Conclusion
Numerous studies have demonstrated the anti-tumor effects of
CX-4945 in leukemias or lymphomas, resulting from inhibition
of CK2 expression (Figure 1). Based on these results, we propose
that CX-4945 has a potential role in novel therapeutic strategies in
the future. Additionally, the combination of CX-4945 with various
other anti-cancer drugs may be a useful therapeutic strategy for
treatment of hematological cancers (Table 1).
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